FCM
Farallon Capital Management Portfolio holdings
AUM
$21.3B
This Quarter Return
+15.74%
1 Year Return
+23.12%
3 Year Return
+87.19%
5 Year Return
+183.94%
10 Year Return
+836.54%
AUM
$14.2B
AUM Growth
+$14.2B
(+4.8%)
Cap. Flow
+$68.9M
Cap. Flow
% of AUM
0.48%
Top 10 Holdings %
Top 10 Hldgs %
50.73%
Holding
123
New
26
Increased
36
Reduced
28
Closed
20
Top Buys
| 1 |
ESRX
Express Scripts Holding Company
ESRX
|
$393M |
| 2 |
Tilray
TLRY
|
$285M |
| 3 |
Equinix
EQIX
|
$263M |
| 4 |
Booking.com
BKNG
|
$254M |
| 5 |
EVHC
Envision Healthcare Holdings Inc
EVHC
|
$207M |
Top Sells
| 1 |
Keurig Dr Pepper
KDP
|
$596M |
| 2 |
XL
XL Group Ltd.
XL
|
$407M |
| 3 |
LOGM
LogMein, Inc.
LOGM
|
$214M |
| 4 |
Gilead Sciences
GILD
|
$207M |
| 5 |
IQVIA
IQV
|
$136M |
Sector Composition
| 1 | Healthcare | 28.73% |
| 2 | Technology | 20.7% |
| 3 | Communication Services | 15.06% |
| 4 | Financials | 14.5% |
| 5 | Industrials | 7.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Liberty Global Class A
LBTYA
$4B
| $192M | 1.13% | 6,629,602 +1,302,109 | +24% | +$37.7M |
|
27
Verisk Analytics
VRSK
$37.5B
| $172M | 1.01% | 1,424,553 -397,149 | -22% | -$47.9M |
|
|
BPYU
28
DELISTED
Brookfield Property REIT Inc. Class A Common Stock
BPYU
| $169M | 1% | +8,054,215 | New | +$169M |
|
29
NXP Semiconductors
NXPI
$59.2B
| $141M | 0.83% | 1,650,000 -1,023,802 | -38% | -$87.5M |
|
30
AstraZeneca
AZN
$248B
| $135M | 0.8% | 3,420,000 -430,000 | -11% | -$17M |
|
31
Equifax
EFX
$30.3B
| $107M | 0.63% | 815,817 -23,142 | -3% | -$3.02M |
|
|
XLRN
32
DELISTED
Acceleron Pharma Inc.
XLRN
| $105M | 0.62% | 1,840,732 +439,732 | +31% | +$25.2M |
|
33
Ascendis Pharma
ASND
$11.8B
| $103M | 0.61% | 1,457,297 | – | – |
|
|
MYOK
34
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $99.8M | 0.59% | 1,531,278 +50,000 | +3% | +$3.26M |
|
|
ZGNX
35
DELISTED
Zogenix, Inc.
ZGNX
| $89.1M | 0.53% | 1,795,500 +100,000 | +6% | +$4.96M |
|
|
SAGE
36
DELISTED
Sage Therapeutics
SAGE
| $88.3M | 0.52% | 625,000 | – | – |
|
37
FibroGen
FGEN
$47.8M
| $84.7M | 0.5% | 1,395,000 -322,500 | -19% | -$19.6M |
|
|
SINA
38
DELISTED
Sina Corp
SINA
| $78.1M | 0.46% | 1,124,224 +489,224 | +77% | +$34M |
|
|
ARRY
39
DELISTED
Array Biopharma Inc
ARRY
| $77.9M | 0.46% | 5,125,000 +475,000 | +10% | +$7.22M |
|
40
Avista
AVA
$2.96B
| $74.3M | 0.44% | 1,470,000 +358,277 | +32% | +$18.1M |
|
41
Enanta Pharmaceuticals
ENTA
$180M
| $74.1M | 0.44% | 867,500 -207,500 | -19% | -$17.7M |
|
42
NovoCure
NVCR
$1.38B
| $70.7M | 0.42% | 1,350,000 -240,000 | -15% | -$12.6M |
|
|
TFCFA
43
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
| $66.5M | 0.39% | 1,435,000 +200,000 | +16% | +$9.27M |
|
44
Alibaba
BABA
$322B
| $61.5M | 0.36% | +373,000 | New | +$61.5M |
|
|
CA
45
DELISTED
CA, Inc.
CA
| $61M | 0.36% | +1,382,361 | New | +$61M |
|
|
RETA
46
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $55.1M | 0.33% | +673,500 | New | +$55.1M |
|
|
AMRN
47
Amarin Corp
AMRN
$311M
| $53.9M | 0.32% | 3,312,700 -1,172,300 | -26% | -$19.1M |
|
48
Iovance Biotherapeutics
IOVA
$807M
| $53.2M | 0.31% | 4,725,000 +300,000 | +7% | +$3.37M |
|
|
GBT
49
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $52.1M | 0.31% | 1,370,000 +185,000 | +16% | +$7.03M |
|
50
CRISPR Therapeutics
CRSP
$4.71B
| $45.2M | 0.27% | 1,018,594 +157,894 | +18% | +$7M |
|